Cited by 141Diabetes Treatment and ManagementDiabetes Management and ResearchMetabolism, Diabetes, and Cancer

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study

Open access

Rosenstock, J., Fonseca, V., McGill, J. B., Riddle, M., Hallé, J. P., Hramiak, I., Johnston, P., Davis, M.·2009·Diabetologia

DOI 10.1007/s00125-009-1452-2PMC PMC2723677

Open this paper in CoChat — free account Open PDF

Abstract

MedDRA Medical

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1007/s00125-009-1452-2

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124
Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: A cohort study
Hemkens, L. G., Grouven, U., Bender, R., Günster, C., Gutschmidt, S., Selke, G. W., & Sawicki, P. T. (2009) · Diabetologia · doi:10.1007/s00125-009-1418-4 · Cited by 607
Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden
Jonasson, J. M., Ljung, R., Talbäck, M., Haglund, B., Gudbjörnsdòttir, S., & Steineck, G. (2009) · Diabetologia · doi:10.1007/s00125-009-1444-2 · Cited by 412
Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group
SDRN Epidemiology Group, & Colhoun, H. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1453-1 · Cited by 387
Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study
Rosenstock, J., Fonseca, V. A., McGill, J. B., Riddle, M. C., Hallé, J., HRAMIAK, I. M., Johnston, P., & Davis, J. L. (2009) · Diabetologia · doi:10.1007/s00125-009-1415-7 · Cited by 87
Self-citation

Show all 5 references

Sorted by citations

Diabetes and Cancer
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
Diabetes and Cancer: A Consensus Report
Giovannucci, E. L., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,082
Insulin Receptor Isoforms and Insulin Receptor/Insulin-Like Growth Factor Receptor Hybrids in Physiology and Disease
Belfiore, A., Frasca, F., Pandini, G., Sciacca, L., & Vigneri, R. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0047 · Cited by 1,058
Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis
DeCensi, A., Puntoni, M., Goodwin, P., Cazzaniga, M., Gennari, A., Bonanni, B., & Gandini, S. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0157 · Cited by 918
Growth hormone, the insulin-like growth factor axis, insulin and cancer risk
Clayton, P., Banerjee, I., Murray, P. G., & Renehan, A. G. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.171 · Cited by 362
Diabetes and cancer: two diseases with obesity as a common risk factor
Garg, S. K., Maurer, H., Reed, K., & SELAGAMSETTY, R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12124 · Cited by 281
Pharmacotherapy of type 2 diabetes: An update
Upadhyay, J., Pοlyzos, S. A., Perakakis, N., Thakkar, B., Paschou, S. Α., Katsiki, N., UNDERWOOD, P. C., Park, K., Seufert, J., Kang, E. S., et al. (2017) · Metabolism · doi:10.1016/j.metabol.2017.08.010 · Cited by 196
Associations of Hyperglycemia and Insulin Usage With the Risk of Cancer in Type 2 Diabetes: The Hong Kong Diabetes Registry
Yang, X., Ko, G. T. C., So, W. Y., Ronald, C. W., Yu, L. W. L., Kong, A. P. S., Zhao, H., Chow, C., Tong, P. C. Y., & Chan, J. C. N. (2010) · Diabetes · doi:10.2337/db09-1371 · Cited by 162
Insulin glargine and malignancy: an unwarranted alarm
Pocock, S., & Smeeth, L. L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61307-6 · Cited by 149
A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations
Evans, M., Schumm‐Draeger, P. ‐., Vora, J. P., & King, A. B. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01395.x · Cited by 147
Combined randomised controlled trial experience of malignancies in studies using insulin glargine
Home, P., & Lagarenne, P. (2009) · Diabetologia · doi:10.1007/s00125-009-1530-5 · Cited by 141
Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Karlstad, Ø., Starup‐Linde, J., Vestergaard, P., Hjellvik, V., Bazelier, M. T., Schmidt, M. K., Andersen, M., Auvinen, A. P., Haukka, J. K., Furu, K., et al. (2013) · Current Drug Safety · doi:10.2174/15680266113136660067 · Cited by 119
Diabetes and Cancer: Is Diabetes Causally Related to Cancer?
Suh, S., & Kim, K. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.3.193 · Cited by 122
Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study
Ruiter, R., Visser, L. E., van Herk‐Sukel, M. P. P., Coebergh, J. W. W., Haak, H. R., Geelhoed-Duijvestijn, P. H. L. M., Straus, S. M. J. M., Herings, R. M. C., & Stricker, B. H. C. (2011) · Diabetologia · doi:10.1007/s00125-011-2312-4 · Cited by 108
Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database
Blin, P., Lassalle, R., Dureau‐Pournin, C., Ambrosino, B., Bernard, M., Abouelfath, A., Gin, H., Jeunne, C. L., Pariente, A., Droz‐Perroteau, C., et al. (2012) · Diabetologia · doi:10.1007/s00125-011-2429-5 · Cited by 94
Further Exploration of the Relationship Between Insulin Glargine and Incident Cancer
Morden, N. E., Liu, S. K., Smith, J., MacKenzie, T. A., Skinner, J., & Korc, M. (2011) · Diabetes Care · doi:10.2337/dc11-0699 · Cited by 94
Latest insights into the risk of cancer in diabetes
Noto, H., Goto, A., Tsujimoto, T., Osame, K., & Noda, M. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12068 · Cited by 90
An injectable and glucose-sensitive nanogel for controlled insulin release
Wu, Z., Zhang, X., Guo, H., Li, C., & Yu, D. (2012) · Journal of Materials Chemistry · doi:10.1039/c2jm34082h · Cited by 87
The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia
Bordeleau, L. J., Yakubovich, N., Dagenais, G. R., Rosenstock, J., Probstfield, J. L., Yu, P. C., Rydén, L., Pīrāgs, V., Spinas, G. A., Birkeland, K. I., et al. (2014) · Diabetes Care · doi:10.2337/dc13-1468 · Cited by 86
Self-citation
(Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus
Semlitsch, T., Engler, J., Siebenhofer, A., Jeitler, K., Berghold, A., & Horvath, K. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005613.pub4 · Cited by 80
Diabetes and Cancer
Chowdhury, T. A. (2010) · QJM · doi:10.1093/qjmed/hcq149 · Cited by 76
Block versus Random Amphiphilic Glycopolymer Nanopaticles as Glucose-Responsive Vehicles
Guo, Q., Zhang, T., An, J., Wu, Z., Zhao, Y., Dai, X., Zhang, X., & Li, C. (2015) · Biomacromolecules · doi:10.1021/acs.biomac.5b01020 · Cited by 75
Importance of Beta Cell Function for the Treatment of Type 2 Diabetes
Saisho, Y. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3030923 · Cited by 75
Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies
Wu, J. W., Filion, K. B., Azoulay, L., Doll, M. K., & Suissa, S. (2016) · Diabetes Care · doi:10.2337/dc15-1816 · Cited by 73
Diabetes mellitus: influences on cancer risk
Szablewski, L. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2573 · Cited by 69
Insulin – Pharmacology, Therapeutic Regimens and Principles of Intensive Insulin Therapy
Donner, T. W., & Sarkar, S. (2015) · Europe PMC (PubMed Central) · Cited by 63
What's fueling the biotech engine—2008
Aggarwal, S. (2009) · Nature Biotechnology · doi:10.1038/nbt1109-987 · Cited by 61
Does Insulin Therapy Promote, Reduce, or Have a Neutral Effect on Cancers?
Gerstein, H. C. (2010) · JAMA · doi:10.1001/jama.2010.60 · Cited by 57
Cancer Incidence and Mortality in Patients with Type 2 Diabetes Treated with Human Insulin: A Cohort Study in Shanghai
Gu, Y., Wang, C., Zheng, Y., Hou, X., Mo, Y., Yu, W., Zhang, L., Hu, C., Nan, H., Chen, L., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053411 · Cited by 55
Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence
Bronsveld, H. K., ter Braak, B., Karlstad, Ø., Vestergaard, P., Starup‐Linde, J., Bazelier, M. T., Bruin, M. L. D., de Boer, A., Siezen, C. L. E., van de Water, B., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0611-2 · Cited by 54
Cancer Risk Associated with Insulin Glargine among Adult Type 2 Diabetes Patients – A Nationwide Cohort Study
Chang, C., Toh, S., Lin, J., Chen, S., Kuo, C.-W., Chuang, L., & Lai, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021368 · Cited by 54
Diabetes and pancreatic cancer.
Muniraj, T., & Chari, S. T. (2012) · PubMed · Cited by 52
Diabetes, antihyperglycemic medications and cancer risk
Gallagher, E. J., & LeRoith, D. (2013) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/01.med.0000433065.16918.83 · Cited by 53
Cancer Risk in Type 2 Diabetes Mellitus: Metabolic Links and Therapeutic Considerations
Sun, G. E. C., & Kashyap, S. R. (2011) · Journal of Nutrition and Metabolism · doi:10.1155/2011/708183 · Cited by 51
Diabetes Mellitus and Increased Risk of Cancer: Focus on Metformin and the Insulin Analogs
McFarland, M. S., & Cripps, R. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.11.1159 · Cited by 50
Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin
Stürmer‎, T., Marquis, M. A., Zhou, H., Meigs, J. B., Lim, S. K., Blonde, L., MacDonald, E. B., Wang, R., LaVange, L. M., Pate, V., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0263 · Cited by 48
Mysterious Metformin
Chong, C. R., & Chabner, B. A. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0286 · Cited by 47
Insulins: Past, Present, and Future
Borgoño, C. A., & Zinman, B. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.002 · Cited by 48
Diabetes and cancer: Epidemiology and potential mechanisms
Joost, H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114550813 · Cited by 45
Insulin Therapy and Cancer
Home, P. (2013) · Diabetes Care · doi:10.2337/dcs13-2002 · Cited by 44
Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial
Rosenstock, J., Fonseca, V. A., Schinzel, S., Dain, M., Mullins, P. R., & Riddle, M. C. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.04.003 · Cited by 44
Self-citation
The Role of Basal Insulin and Glucagon-Like Peptide-1 Agonists in the Therapeutic Management of Type 2 Diabetes—A Comprehensive Review
Garg, S. K. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2009.0127 · Cited by 38
The metabolic and mitogenic properties of basal insulin analogues
Tennagels, N., & Ulrich, W. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2012.754474 · Cited by 38
Type 2 diabetes mellitus and risk of malignancy: is there a strategy to identify a subphenotype of patients with increased susceptibility to endogenous and exogenous hyperinsulinism?
Müssig, K., Staiger, H., Kantartzis, K., Fritsche, A., Kanz, L., & Häring, H. (2010) · Diabetic Medicine · doi:10.1111/j.1464-5491.2010.03132.x · Cited by 37
Insulin Glargine and Cancer Risk in Patients with Diabetes: A Meta-Analysis
Tang, X., Yang, L., He, Z., & Liu, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051814 · Cited by 37
Insulin—Carcinogen or Mitogen? Preclinical and Clinical Evidence from Prostate, Breast, Pancreatic, and Colorectal Cancer Research
Call, R., Grimsley, M., Cadwallader, L., Cialone, L., Hill, M., Hreish, V., King, S., & Riche, D. M. (2010) · Postgraduate Medicine · doi:10.3810/pgm.2010.05.2153 · Cited by 37
Cancer with Diabetes: Prevalence, Metabolic Control, and Survival in an Academic Oncology Practice
Karlin, N. J., Dueck, A. C., & Cook, C. B. (2012) · Endocrine Practice · doi:10.4158/ep12128.or · Cited by 37
Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study
Buchs, A. E., & SILVERMAN, B. G. (2011) · Metabolism · doi:10.1016/j.metabol.2011.05.002 · Cited by 34
Diabetes, insulin treatment, and cancer risk: what is the evidence?
Azar, M., & Lyons, T. J. (2009) · F1000 Medicine Reports · doi:10.3410/m2-4 · Cited by 31
Review on the In Vitro Interaction of Insulin Glargine with the Insulin/Insulin-like Growth Factor System: Potential Implications for Metabolic and Mitogenic Activities
Ciaraldi, T. P., & Sasaoka, T. (2010) · Hormone and Metabolic Research · doi:10.1055/s-0030-1267203 · Cited by 28
Antihyperglycaemic therapies and cancer risk
Lutz, S. Z., Staiger, H., Fritsche, A., & Häring, H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114549553 · Cited by 28
Glucose Metabolism Disorders and the Risk of Cancer
Piątkiewicz, P., & Czech, A. (2011) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-011-0119-0 · Cited by 26
Synthetic Insulin Analogs and Their Use in Dogs and Cats
Gilor, C., & Graves, T. K. (2010) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2009.11.001 · Cited by 25
Do we have enough data to confirm the link between antidiabetic drug use and cancer development?
Drzewoski, J., Drozdowska, A., & Śliwińska, A. (2011) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.1029 · Cited by 25
Insulin Glargine and Risk of Cancer: A Meta-Analysis
Du, X., Zhang, R., Xue, Y., Li, D., Cai, J., Zhou, S., Huang, Z., Yu, R., & Liu, Y. (2012) · The International Journal of Biological Markers · doi:10.5301/jbm.2012.9349 · Cited by 23
Diabetes and cancer relationships (糖尿病与肿瘤的关联性)
Wang, T., Ning, G., & Bloomgarden, Z. T. (2013) · Journal of Diabetes · doi:10.1111/1753-0407.12057 · Cited by 21
Insulin glargine use and breast cancer risk: Associations with cumulative exposure
Peeters, P. J. H. L., Bazelier, M. T., Leufkens, H. G. M., Auvinen, A. P., van Staa, T. P., de Vries, F., & Bruin, M. L. D. (2016) · Acta Oncologica · doi:10.3109/0284186x.2016.1155736 · Cited by 22
Long-term insulin glargine therapy in type 2 diabetes mellitus: a focus on cardiovascular outcomes
Donner, T. W., & Joseph, J. J. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s50286 · Cited by 21
Insulin Therapy and Cancer in Type 2 Diabetes
Mannucci, E. (2012) · ISRN Endocrinology · doi:10.5402/2012/240634 · Cited by 21
Diabetes: glycaemic control in type 2 (drug treatments).
Gorter, K. J., de Laar, F. A. V., Janssen, P. G. H., Houweling, S. T., & Rutten, G. E. H. M. (2012) · Europe PMC (PubMed Central) · Cited by 19
Impaired Glucose Metabolism, Anti-Diabetes Medications, and Risk of Thyroid Cancer
Kushchayeva, Y. S., Kushchayev, S. V., Jensen, K. E., & Brown, R. J. (2022) · Cancers · doi:10.3390/cancers14030555 · Cited by 19
Diabetes and risk of tumors: oncologic considerations
Rosta, A. (2011) · Orvosi Hetilap · doi:10.1556/oh.2011.29158 · Cited by 19
Controversies in the use of insulin analogues
Werner, H., Weinstein, D., Yehezkel, E., & Laron, Z. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.540233 · Cited by 18
Cancer Specific Mortality in Insulin-Treated Type 2 Diabetes Patients
Ioacără, S., Guja, C., Ionescu-Tirgoviste, C., Fica, S. V., & Roden, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0093132 · Cited by 18
Advances in Pharmacologic Therapies for Type 2 Diabetes
Morsink, L. M., Smits, M. M., & Diamant, M. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-012-0302-8 · Cited by 18
Non-Insulin Antidiabetic Agents and Lung Cancer Risk in Drug-Naive Patients with Type 2 Diabetes Mellitus: A Nationwide Retrospective Cohort Study
Tabernacki, T., Wang, L., Kaelber, D. C., Xu, R., & Berger, N. A. (2024) · Cancers · doi:10.3390/cancers16132377 · Cited by 16
Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms
Raz, I., & Eldor, R. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2265 · Cited by 14
Glargine and Cancer: Can We Now Suggest Closure?
Owens, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-1968 · Cited by 14
Putting Insulin Glargine and Malignancies into Perspective
Ehninger, G., & Schmidt, A. H. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0206 · Cited by 13
Long-acting basal insulin analogs: latest developments and clinical usefulness
Mavrogiannaki, A. N., & Migdalis, I. N. (2012) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622312454158 · Cited by 13
The longest ever randomised controlled trial of insulin glargine: study design and HbA1c findings
Currie, C. J. (2009) · Diabetologia · doi:10.1007/s00125-009-1477-6 · Cited by 12
The path to approval of new drugs for diabetes
Rendell, M. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.770470 · Cited by 12
Detemir as a once-daily basal insulin in type 2 diabetes
Nelson (2011) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s19539 · Cited by 11
Looking at the carcinogenicity of human insulin analogues via the intrinsic disorder prism
Redwan, E. M. M. M., Linjawi, M. H., & Uversky, V. N. (2016) · Scientific Reports · doi:10.1038/srep23320 · Cited by 11
Therapie des Typ-2-Diabetes
Landgraf, R., Kellerer, M., Aberle, J., Fach, E.-M., Gallwitz, B., Hamann, A., Joost, H., Klein, H., Müller‐Wieland, D., Nauck, M. A., et al. (2018) · Diabetologie und Stoffwechsel · doi:10.1055/a-0598-0475 · Cited by 11
Novel Experimental and Clinical Therapeutic Uses of Low-Molecular-Weight Heparin/Protamine Microparticles
Kishimoto, S., Ishihara, M., Takikawa, M., Mori, Y., Hattori, H., Fujita, M., & Nakamura, S. (2012) · Pharmaceutics · doi:10.3390/pharmaceutics4010042 · Cited by 10
Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics
Floch, J. P. L. (2010) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmsott.s7315 · Cited by 10
The Impact of Diabetes Mellitus on the Second Primary Malignancies in Colorectal Cancer Patients
Halámková, J., Kazda, T., Pehalová, L., Goněc, R., Kozáková, Š., Bohovicová, L., Slabý, O., Demlová, R., Svoboda, M., & Kišš, I. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.573394 · Cited by 9
Role and application of hysterosalpingography and Fallopian tube recanalization.
Mallarini, G., & Saba, L. (2010) · PubMed · Cited by 9
Protected Graft Copolymer (PGC) Basal Formulation of Insulin as Potentially Safer Alternative to Lantus® (Insulin-Glargine): A Streptozotocin-Induced, Diabetic Sprague Dawley Rats Study
Reichstetter, S., Castillo, G. M., Lai, M., Nishimoto-Ashfield, A., Banerjee, A. A., Bogdanov, A. A., Jr., Lyubimov, A. V., & Bolotin, E. M. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0646-8 · Cited by 8
Diabetes, Antihyperglycemic Medications and Cancer Risk: Smoke or Fire?
Gallagher, E. J., & LeRoith, D. (2013) · Endocrine Practice · doi:10.4158/ep13190.ra · Cited by 8
Insulin glargine and cancer: cause and effect unproven
Owens, D. R., Rosenstock, J., & Bolli, G. B. (2009) · Practical Diabetes · doi:10.1002/pdi.1388 · Cited by 8
Self-citation
Insufficient evaluation of adverse events is not a proof of safety
Hemkens, L. G., Grouven, U., Bender, R., & Sawicki, P. T. (2010) · Diabetologia · doi:10.1007/s00125-009-1654-7 · Cited by 8
Development and Validation of an Image Analysis System for the Measurement of Cell Proliferation in Mammary Glands of Rats
Lindauer, K., Bartels, T., Scherer, P., & Kabiri, M. (2019) · Toxicologic Pathology · doi:10.1177/0192623319863129 · Cited by 7
Is Insulin Therapy Safe?
Home, P., & Itzhak, B. (2019) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001077 · Cited by 7
Impaired glucose metabolism treatment and carcinogenesis
Matyszewski, A., Czarnecka, A. M., Kawecki, M., KORZEŃ, P., SAFIR, I. J., Kukwa, W., & Szczylik, C. A. (2015) · Oncology Letters · doi:10.3892/ol.2015.3324 · Cited by 7
Cancer Risk in Type 2 Diabetes
Kong, A. P. S., & Chan, J. C. N. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0277-4 · Cited by 7
Electronic Medical Record Cancer Incidence over Six Years Comparing New Users of Glargine with New Users of NPH Insulin
Lim, S. K., Stember, K. G., He, W. W., Porneala, B., Yelibi, C., Marquis, A., Stürmer‎, T., Buse, J. B., & Meigs, J. B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109433 · Cited by 7
Long-term exposure to insulin and volumetric mammographic density: observational and genetic associations in the Karma study
Borgquist, S., Rosendahl, A. H., Czene, K., Bhoo‐Pathy, N., Dorkhan, M., Hall, P. N., & Brand, J. S. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-1026-7 · Cited by 7
Insulin Glargine and Cancer Risk: An Opinion Statement of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy
Edwards, K. L., Riche, D. M., Stroup, J. S., Goldman, J. D., Vellurattil, R. P., Cross, L. B., & Kane, M. P. (2010) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.9.955 · Cited by 6
Optimizing treatment strategies with insulin glargine in Type 2 diabetes
Owens, D. R. (2012) · Expert Review of Endocrinology & Metabolism · doi:10.1586/eem.12.29 · Cited by 5
Solid Phase Synthesis of an Analogue of Insulin, A0:R glargine, That Exhibits Decreased Mitogenic Activity
Kwak, S., Forbes, B. E., Lee, Y., Belgi, A., Wade, J. D., & Hossain, M. A. (2010) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-010-9218-8 · Cited by 5
India suspends pioglitazone: Is it justified?
SADIKOT, S. M., & Ghosal, S. (2014) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2013.10.020 · Cited by 5
Insulin Concerns and Promises
Bloomgarden, Z. T. (2011) · Diabetes Care · doi:10.2337/dc11-0591 · Cited by 5
Análogos de insulina: modificaciones en la estructura, consecuencias moleculares y metabólicas
de Luis, D. A., & Romero, E. (2012) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2012.04.010 · Cited by 5
Regulatory Forum Opinion Piece
Bartels, T., Wäse, K., Heinrichs, M., Stolte, M., Roome, N. O., Scherer, P., & Lindauer, K. (2016) · Toxicologic Pathology · doi:10.1177/0192623316665721 · Cited by 5
The insulin glargine dilemma: an opportunity for the diabetes community?
Stümvoll, M., & Nawroth, P. P. (2009) · Diabetologia · doi:10.1007/s00125-009-1490-9 · Cited by 5
Potential Mechanisms Linking Insulin to Cancer
Babichev, Y., Khalid, S., & Fantus, I. G. (2011) · Energy balance and cancer · doi:10.1007/978-1-4419-9911-5_7 · Cited by 4
Choice of Long-Acting Insulin Therapy for Type 2 Diabetes
Krentz, A. J., & Sinclair, A. J. (2011) · Drugs & Aging · doi:10.2165/11597820-000000000-00000 · Cited by 4
Insulin, other hypoglycemic drugs, and glucagon
Page, R. C. L. (2011) · Side effects of drugs annual · doi:10.1016/b978-0-444-53741-6.00042-8 · Cited by 3

Authors: Rosenstock, J., Fonseca, V., McGill, J. B., Riddle, M., Hallé, J. P., Hramiak, I., Johnston, P., & Davis, M.
Affiliations: The University of Texas Southwestern Medical Center (US)
Tulane University (US)
Washington University in St. Louis (US)
Oregon Health & Science University (US)
Université de Montréal (CA)
Western University (CA)
University of Wisconsin–Madison (US)
Corresponding author: Rosenstock, J.
ORCID: Rosenstock, J.
Fonseca, V.
McGill, J. B.
Riddle, M.
Hramiak, I.
Venue: Diabetologia
Publisher: Springer Science and Business Media LLC
Published: 2009-07-16
Volume: 52
Issue: 9
Pages: 1971-1973
ISSN: 0012-186X (ISSN-L)
1432-0428
DOI: 10.1007/s00125-009-1452-2
PMC: PMC2723677
OpenAlex: W2135096382
Cited by: 141
References: 5
Citations by year: 2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 1 · 2019: 3 · 2018: 3 · 2017: 1 · 2016: 5 · 2015: 6 · 2014: 14 · 2013: 16 · 2012: 16
FWCI: 20.88
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc
Locations: Diabetologia (publishedVersion, cc-by-nc)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: American Diabetes Association
Amgen
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
GlaxoSmithKline
Sanofi
Tulane University
McGill University
MannKind Corporation
Daiichi-Sankyo
Novo Nordisk
National Institutes of Health
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords: insulin glargine, neutral protamine Hagedorn insulin, type 2 diabetes, cancer risk, cancer incidence, long-acting insulin, insulin analogues
MeSH terms: Insulin Glargine, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Humans, Hypoglycemic Agents, Insulin, Insulin, Isophane, Neoplasms, Risk Factors, Insulin, Long-Acting

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks